+548.8%
MU vs MRNA
+485.7%
+63.0%
-39.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | +5.4% | -5.6% | -0.4% |
| 7D | -4.1% | -1.1% | -3.0% | -4.0% |
| 30D | +7.0% | +126.1% | -119.1% | +2.1% |
| 3M | -2.1% | +190.0% | -192.1% | -15.4% |
| 6M | +133.1% | +157.2% | -24.2% | +107.0% |
| YTD | +241.9% | +388.2% | -146.3% | +154.3% |
| 1Y | +548.8% | +467.0% | +81.7% | +363.4% |
| All | +548.8% | +485.7% | +63.0% | +363.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling